{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018576","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.038426+00:00","generated_at":"2026-06-02T03:42:19.897798+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026","bullets":["Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.","Net income $0.8M vs net loss $4.4M in prior year.","Cash $16.3M; expects cash runway into Q1 2026.","PUR1900 Phase 2b stopped (no safety concern); Pulmatrix bears no further dev cost, gets 2% royalty on ex-US sales.","PUR3100 Phase 2-ready; seeking partnership for Phase 2 study."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018576","json":"https://secwatch.observer/filing/0001493152-24-018576.json","markdown":"https://secwatch.observer/filing/0001493152-24-018576.md","text":"https://secwatch.observer/filing/0001493152-24-018576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/0001493152-24-018576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:42:19.897798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6103f9307ca78a95fc81e0993788f756e166c75b","claim":"Pulmatrix, Inc. reported three months ended March 31, 2024 results: revenue $5.9 million, net income $0.8 million.","evidence_excerpt":"outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900. First Quarter 2024 Financial Results Revenues increased $4.4 million to $5.9 million for the three months ended March 31, 2024, compared to $1.5 million for the three months ended March 31, 2023. The increase is primarily related to a contract modification of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315224018576/0001493152-24-018576-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$5.9 million"},{"label":"Net income","value":"$0.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}